Active substance
Tetracosactide
- SFDA 2
- Health Canada 1
- NHS prices 1
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| SYNACTHEN DEPOT | 1 mg/ml | Suspension for injection · Intramuscular use | 1 Ampoule | SAR 1698.00 | Biological · Prescription | Atnahs Pharma UK Limited | Valid |
| SYNACTHEN DEPOT | 1 mg/ml | Suspension for injection · Intramuscular use | 1 Ampoule | SAR 20.00 | Biological · Prescription | NOVARTIS | Withdrawn by MAH · Not Marketed |
Canada Canada — marketed products (Health Canada)
| Brand | DIN | Strength | Form · route | Company |
|---|---|---|---|---|
| CORTROSYN INJ 0.25MG | 00022381 | 0.25 MG / VIAL | POWDER FOR SOLUTION · INTRAVENOUS; INTRAMUSCULAR | AMPHASTAR PHARMACEUTICALS, INC. |
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| NHS Drug Tariff | Tetracosactide 250micrograms/1ml solution for injection ampoules | £38.00 | 1 ampoule | 1 Oct 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.